CEO Exit Adds To Iovance Woes After Cell Therapy Setback

Filing Set Back Until 2022

 
• By Andrew McConaghie
  
Iovance Philadelphia Navy Yard rendering
The company's GMP cell therapy manufacturing facility in Navy Yard, Philadelphia is expected to be completed this year. • Source: DIGSAU

More from Business

More from Scrip